Standard Biotools INC Form 4 insider transactions
NASDAQ
Jeffrey G. Black, SVP & Chief Financial Officer of Standard BioTools Inc., reports acquisition of shares and options.
NASDAQ
Hanjoon Alex Kim, Chief Operating Officer of Standard Biotools Inc., reports acquisition of shares and options in the company.
NASDAQ
Casdin Partners Master Fund, L.P. and related entities have increased their holdings in Standard BioTools Inc. (LAB) through a series of open market purchases between May 15 and May 17, 2024.
NASDAQ
Jeffrey G. Black, SVP & Chief Financial Officer of Standard BioTools Inc., reports the vesting of restricted stock units and subsequent stock transactions.
NASDAQ
Michael Egholm, CEO of Standard BioTools Inc., disposed of 102,564 shares of common stock on April 8, 2024, to cover tax obligations related to vesting performance-based restricted stock units.
NASDAQ
CEO Michael Egholm reports acquisition and vesting of Standard BioTools stock, including shares received from the SomaLogic merger and performance-based restricted stock units.
NASDAQ
Hanjoon Alex Kim, Chief Operating Officer of Standard BioTools Inc., reports transactions involving restricted stock units (RSUs) and common stock.
NASDAQ
Casdin Partners and related entities acquire a substantial amount of Standard BioTools Inc. common stock and dispose of convertible preferred stock.
NASDAQ
Form 4: Casdin Partners Increases Stake in Standard BioTools Inc. (LAB) Following Recent Transactions
Casdin Partners and related entities report acquiring additional shares of Standard BioTools Inc. (LAB) common stock, increasing their total holdings.